US-based Abbott Laboratories (NYSE: ABT) has announced the successful application of its transcatheter aortic valve implantation (TAVI) balloon-expandable system in treating the first patient with symptomatic severe aortic stenosis. This milestone marks a significant step forward in the company’s efforts to provide advanced heart valve therapies.
Pioneering Software-Guided TAVI System
The product represents the initial phase of Abbott’s journey toward a software-guided balloon-expandable TAVI system, designed to lay the groundwork for artificial intelligence (AI) guided procedures. This innovative approach aims to enhance the precision and effectiveness of TAVI treatments, leveraging the power of AI to improve patient outcomes.
Expanding Abbott’s Structural Heart Portfolio
Upon completion of clinical development and regulatory approval, Abbott’s TAVI system will join the company’s existing Navitor TAVI system, which is already commercially available. This new addition will offer physicians an additional management option for TAVI procedures, further expanding Abbott’s structural heart portfolio and meeting the diverse needs of patients with aortic stenosis.-Fineline Info & Tech
Leave a Reply